Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.

Saved in:
Bibliographic Details
Title: Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.
Authors: Servitja S; Hospital del Mar, Hospital del Mar Research Institute Barcelona, Barcelona, Spain. sservitja@hmar.cat.; Universitat Pompeu Fabra, Barcelona, Spain. sservitja@hmar.cat.; GEICAM, Spanish Breast Cancer Group, Madrid, Spain. sservitja@hmar.cat.; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain. sservitja@hmar.cat., Carrasco E; GEICAM, Spanish Breast Cancer Group, Madrid, Spain., Andrés R; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain., Rodríguez-Lescure Á; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital General Universitario de Elche, Elche, Spain., Martín M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.; Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain., Ruiz-Borrego M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario Virgen del Rocío, Sevilla, Spain., Guerrero Á; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Instituto Valenciano de Oncología, Valencia, Spain., Bermejo B; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Clínico Universitario de Valencia, Valencia, Spain., Antón A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario Miguel Servet, Zaragoza, Spain., Muñoz M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Clinic i Provincial, Barcelona, Spain., Margeli M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario Germans Trias i Pujol, Badalona, Spain., Álvarez I; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital de Donostia, San Sebastián, Spain., Fernández LA; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain., Ponce J; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital General Universitario de Alicante, Alicante, Spain., Cruz J; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Martínez P; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario Basurto, Bilbao, Spain., López-Tarruella S; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.; Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain., Amenedo M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Centro Oncológico de Galicia, La Coruña, Spain., Blasco A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain., Polonio Ó; GEICAM, Spanish Breast Cancer Group, Madrid, Spain., Gil-Gil M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Instituto Catalán de Oncología-Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain.
Source: Breast cancer research : BCR [Breast Cancer Res] 2026 May 25; Vol. 28 (1). Date of Electronic Publication: 2026 May 25.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1465-542X
DOI:10.1186/s13058-026-02300-0